Montana has become the first U.S. state to create a parallel drug approval pathway that circumvents federal Food and Drug Administration oversight. As of this week, biotech companies can pay $12,500 to submit experimental drugs to a newly established state review board for approval, provided the drugs have completed preliminary testing—sometimes involving as few as 10 healthy subjects. The state review board, whose specific composition and evaluation criteria remain partially undefined in available reporting, will determine whether drugs can be marketed directly to Montana consumers. This represents a significant departure from the FDA's standard drug approval process, which typically requires multiple phases of clinical trials involving hundreds or thousands of participants before market authorization. The move reflects Montana's effort to position itself as an experimental medical hub and respond to families seeking treatments for conditions without existing therapeutic options.
The policy gained momentum through individual cases, particularly that of Brody DeVault, a young child with developmental delays whose family sought access to experimental treatments not yet approved through federal channels. Montana's 'right to try' framework stems from broader national frustration with FDA approval timelines and the limited access terminally ill or severely affected patients have to investigational therapies. However, the specific approval standards for Montana's review board remain opaque. Available sources do not clarify whether reviewers will require efficacy data, what safety thresholds must be met, or how the board will evaluate risk-benefit ratios compared to no treatment alternatives. The $12,500 application fee creates a financial incentive for biotech companies, though no companies have yet publicly announced plans to pursue Montana approval. Questions persist about whether out-of-state biotech firms view this as a viable commercial pathway or a public relations opportunity.
The Montana precedent may influence drug regulation nationwide, though actual legislative momentum elsewhere remains unclear. No other states have reportedly drafted comparable bills, suggesting this represents a state-level experiment rather than an emerging national trend. Biotech industry representatives and patient advocacy groups have expressed cautious interest, while medical regulators and pharmaceutical safety experts have not publicly commented on the framework's implications. The policy raises fundamental questions about regulatory fragmentation: whether other states will establish competing approval standards, whether Montana's framework will attract legitimate therapeutic research or primarily unproven treatments, and how federal regulators will respond if this model gains traction. The coming months will determine whether Montana's experiment becomes a model for expanded access or a cautionary example of regulatory gaps.